Press Releases
January 23, 2017
Debiopharm Investment strengthens its presence in the renewable energy sector
January 11, 2017
GenePOC to Announce CE Marking of its revogene™ Instrument and its Second Test, CDiff
January 10, 2017
Debiopharm International SA Announces positive Phase 2 Clinical Trial with Debio 1450 in ABSSSI patients
January 9, 2017
Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe
November 25, 2016
Les projets «Hello Mask» et «Le 5ème mur» remportent le Challenge Debiopharm-Inartis 2016 sur la Qualité de Vie des Patients
November 3, 2016
GenePOC announces setup of an extensive network of commercial partners across Europe for Distribution
October 25, 2016
Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450